Icosavax, Inc.
NASDAQ:ICVX
15.31 (USD) • At close February 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Revenue
| 0.582 | 7.802 | 1.616 | 0 |
| Cost of Revenue
| 1.843 | 0.082 | 17.667 | 4.157 |
| Gross Profit
| -1.261 | 7.72 | -16.051 | -4.157 |
| Gross Profit Ratio
| -2.167 | 0.989 | -9.933 | 0 |
| Reseach & Development Expenses
| 65.41 | 38.776 | 17.667 | 4.157 |
| General & Administrative Expenses
| 30.23 | 34.887 | 2.659 | 1.241 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 |
| SG&A
| 30.23 | 34.887 | 2.659 | 1.241 |
| Other Expenses
| -0.582 | -7.802 | -1.616 | 0 |
| Operating Expenses
| 95.058 | 65.861 | 18.71 | 5.398 |
| Operating Income
| -95.058 | -65.861 | -18.71 | -5.398 |
| Operating Income Ratio
| -163.33 | -8.442 | -11.578 | 0 |
| Total Other Income Expenses Net
| 3.3 | -1.11 | -0.144 | 0.101 |
| Income Before Tax
| -91.758 | -66.971 | -18.854 | -5.297 |
| Income Before Tax Ratio
| -157.66 | -8.584 | -11.667 | 0 |
| Income Tax Expense
| -3.3 | 1.028 | 0.331 | -0.101 |
| Net Income
| -88.458 | -67.999 | -19.185 | -5.196 |
| Net Income Ratio
| -151.99 | -8.716 | -11.872 | 0 |
| EPS
| -2.23 | -3.78 | -6.67 | -0.51 |
| EPS Diluted
| -2.23 | -3.78 | -6.67 | -0.51 |
| EBITDA
| -95.058 | -64.902 | -18.709 | -5.398 |
| EBITDA Ratio
| -163.33 | -8.319 | -11.577 | 0 |